The U.S. Food and Drug Administration (FDA) has officially shifted its policy, now requiring only a single pivotal clinical trial for the approval of novel medicines. This significant departure from the decades-old standard of two adequate and well-controlled studies aims to streamline drug development and potentially lower costs for patients.
This policy update, driven by advancements in precision medicine and scientific understanding, allows for more targeted research. The FDA argues that modern techniques like genomic sequencing and molecular modeling provide a deeper biological understanding of drug interactions, negating the need for a second confirmatory trial. The agency believes this change will address a key justification for high drug launch prices by reducing research and development expenditures.
Despite some internal friction, the FDA maintains that this move focuses on evidentiary standards rather than lowering them. The single trial will be combined with confirmatory evidence to form the basis for marketing authorization, alongside a post-market initiative to collect robust data on all approved drugs. This pivot represents a strategic bet on the predictive power of contemporary science to accelerate innovation and reduce financial burdens.